Original Article

The effect of a single-strain probiotic administration in the treatment of thermal burns patients

Abstract

Background and Objectives: Between 2007 and 2011, the mortality rate for burns patients at Dr. Soetomo General Hospital, Surabaya, Indonesia was 14.1% and 60% were suspected to be sepsis-related. Immunosuppression, gut barrier disruption, and intestinal hypomotility cause bacterial and bacterial product translocation. Probiotics improve the intestinal microbiome and eventually reduce bacterial translocation, and an increased secretory immunoglobulin A (SIgA) secretion post-administration of a multi-species probiotic has been observed. We aimed to determine whether a single-strain probiotic administration could show strengthened intestinal immunity, through an increase in SIgA levels, as with multi-strain probiotics.
Materials and Methods: Sixteen burns patients from our hospital Burns Centre were randomized into three treatment groups, and the patients were administered either a placebo, a Lactobacillus reuteri protectis probiotic, or a Bifidobacterium infantis 35624 probiotic for 14 consecutive days. The SIgA levels were analyzed using ELISA pre- and post-treatment.
Results: The post-treatment SIgA levels in the placebo, Lactobacillus reuteri protectis probiotic, and Bifidobacterium infantis 35624 probiotic groups were 222.56±74.22 mg/dL, 223.92±68.89 mg/dL, and 332.38±64.27 mg/dL, respectively. Decreased SIgA levels were observed in the placebo (7.19±15.87) and in the Lactobacillus reuteri protectis probiotic (1.9920±14.76) groups, whereas an increase was seen in the SIgA level in the Bifidobacterium infantis 35624 probiotic group (58.26±77.41).
Conclusion: The Bifidobacterium infantis 35624 single-strain probiotic is generally superior to Lactobacillus reuteri protectis in altering intestinal immunity; however, this finding was not statistically significant. A multi-strain probiotic supplement is recommended for burns patients.

1. Wurzer P, Culnan D, Cancio LC, Kramer GC. Pathophysiology of Burn Shock and Burn Edema. In: Herndon DN, editor. Total Burn Care. 5th ed. Elsevier; 2018. p. 66-76.
2. Huang G, Sun K, Yin S, Jiang B, Chen Y, Gong Y, et al. Burn injury leads to increase in relative abundance of opportunistic pathogens in the rat gastrointestinal microbiome. Front Microbiol 2017; 8:1237.
3. Beckmann N, Pugh AM, Caldwell CC. Burn injury alters the intestinal microbiome’s taxonomic composition and functional gene expression. PLoS One 2018;13(10):e0205307.
4. Hidayat TSN, Noer MS, Saputro ID. Five years retrospective study of burns in Dr. Soetomo General Hospital Surabaya. FMI 2014; 50:123-130.
5. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237-238.
6. Azizpour K, Bahrambeygi S, Mahmoodpour S, Azizpour A. History and basics of probiotics. Res J Biol Sci 2009;4:409-426.
7. Mayes T, Gottschlich MM, James LE, Allgeier C, Weitz J, Kagan RJ. Clinical safety and efficacy of probiotic administration following burn injury. J Burn Care Res 2015; 36:92-99.
8. El-Ghazely MH, Mahmoud WH, Atia MA, Eldip EM. Effect of probiotic administration in the therapy of pediatric thermal burn. Ann Burns Fire Disasters 2016; 29:268-272.
9. Tahir S, Makhdoom A, Awan S, Ali SA. Role of probiotics in the management of burns patients. World J Med Sci 2014; 11:417-421.
10. Toliver-Kinsky T, Kobayashi M, Suzuki F, Sherwood ER. The Systemic Inflammatory Response Syndrome. In: Herndon DN, editor. Total Burn Care. 5th ed. Elsevier; 2018. p. 205-220.
11. Balzan S, De Almeida Quadros C, De Cleva R, Zilberstein B, Cecconello I. Bacterial translocation: Overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2007;22:464-471.
12. Kobayashi M, Toliver-Kinsky T, Suzuki F. Defense antibacterial effector cells influenced by assive Burns. In: Herndon DN, editor. Total Burn Care. 5th ed. Elsevier; 2018. p. 221-231.
13. Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol Rev 2005;206:64-82.
14. Alberda C, Gramlich L, Meddings J, Field C, Mccargar L, Kutsogiannis D, et al. Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007;85:816-823.
15. Townsend JR, Bender D, Vantrease WC, Sapp PA, Toy AM, Woods CA, et al. Effects of probiotic (Bacillus subtilis DE111) supplementation on immune function, hormonal status, and physical performance in division I baseball players. Sports (Basel) 2018; 6(3): E70.
16. Bengmark S. Synbiotics and the mucosal barrier in critically ill patients. Curr Opin Gastroenterol 2005;21:712-716.
17. Magnotti LJ, Deitch EA. Burns, bacterial translocation, gut barrier function, and failure. J Burn Care Rehabil 2005;26:383-391.
18. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune response during health and disease. Nat Rev Immunol 2009;9:313-323.
19. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012;30:759-795.
20. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis 2015;60:S129-134.
Files
IssueVol 11 No 3 (2019) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v11i3.1335
Keywords
Probiotic Microbiome Bacterial translocation Lactobacillus Bifidobacterium
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Perdanakusuma D, Hariani L, Nasser NF, Datusanantyo RA. The effect of a single-strain probiotic administration in the treatment of thermal burns patients. Iran J Microbiol. 2019;11(3):255-259.